Immune checkpoint inhibitors (ICIs) are rapidly changing practice across different tumor settings. With this article, we reflect on how to assimilate the tsunami of ICIs data into clinical practice.
A tremendous increase on approvals, number of publications, and clinical trials ongoing with ICIs on many different tumor types.
ICIs are innovative treatments that are showing a significant benefit on different tumors. More approvals and an explosive increase of knowledge around the usage of ICI are to be expected in the near future, bringing new challenges on how to integrate this fast-growing evidence with ICI into clinical practice. To be updated, oncologists could follow approved guidelines from relevant societies and complement it with an appropriate search from publication databases. There are also some available courses, conferences and online material that are useful to improve knowledge in this so rapidly changing environment. In the future, we believe the integration of artificial intelligence and learning machines will play an important role to facilitate best clinical practices in different fields of medicine but particularly for oncology.
aDepartment of Medical Oncology, Centro Hospitalar e Universitário do Algarve, Faro
bDepartment of Epidemiology, Escola Nacional de Saúde Pública, Universidade Nova de Lisboa, Lisboa, Portugal
cDepartment of Medical Oncology, UZBrussel, Jette
dDepartment of Medical Oncology, Hopital erasme, Anderlecht
eDepartment of Oncology Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
Correspondence to Luís Castelo-Branco, MD, PharmD, Centro Hospitalar e Universitário do Algarve, Serviço de Oncologia Médica, R. Leao Penedo, 8000-386 Faro, Portugal. Tel: +351918288881; e-mail: email@example.com